Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. We show 21 historical shares outstanding datapoints in our LUMO shares outstanding history coverage, used to compute LUMO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LUMO market cap history over the course of time is important for investors
interested in comparing LUMO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LUMO versus a peer is one thing; comparing
LUMO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LUMO can fluctuate over the course of history.
With this page we aim to empower investors researching LUMO by allowing them to research the LUMO market cap history. |
Free LUMO Email Alerts:
Video: The Importance of Market Cap
